Scientists hunt for Cancer's 'Achilles Heel' to target with immune drugs
NCT ID NCT04957615
Summary
This study aims to learn if two specific markers found in tumor tissue can help doctors predict which patients with advanced solid cancers will benefit most from immunotherapy. Sixteen patients with specific genetic mutations in their tumors will receive the immunotherapy drug nivolumab. Researchers will track how well patients respond and look for patterns between the tumor markers and treatment outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.